Galderma's Nemluvio Shows Sustained Efficacy Over Three Years in…

Event summary

Galderma presented three-year data from the ARCADIA long-term extension study at EADV 2026, showing sustained improvements in skin lesions, itch, sleep disturbance, and quality of life for patients with moderate-to-severe atopic dermatitis.
Up to 91% of patients achieved at least 75% improvement in eczema severity (EASI-75), and up to 75% achieved at least 90% improvement (EASI-90).
Nemluvio demonstrated a favorable safety profile with no new safety signals identified through three years of treatment.
Additional data highlighted Nemluvio's efficacy in prurigo nodularis, with sustained improvements in itch, pain, sleep disturbance, and quality of life.

The big picture

Galderma's three-year data for Nemluvio underscores the growing importance of long-term efficacy and safety profiles in the competitive dermatology market. As chronic skin diseases like atopic dermatitis and prurigo nodularis gain attention, the ability to demonstrate sustained benefits could differentiate Nemluvio in a field increasingly focused on patient-centric outcomes. The data also highlight Galderma's strategic focus on therapeutic dermatology, reinforcing its position as a pure-play leader in the category.

What we're watching

Market Expansion: Whether Galderma can leverage these long-term efficacy data to expand Nemluvio's approvals and market reach in additional countries and indications.
Competitive Positioning: How these sustained efficacy results position Nemluvio against emerging therapies in the atopic dermatitis and prurigo nodularis markets.
Regulatory Dynamics: The pace at which regulatory bodies may approve Nemluvio for broader patient populations based on these long-term data.